Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co KgfiledCriticalBoehringer Ingelheim Pharma
Priority to UY27241ApriorityCriticalpatent/UY27241A1/en
Publication of UY27241A1publicationCriticalpatent/UY27241A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
El presente invento se refiere a indolinonas sustituidas en posición 6 de la fórmula general (I) en la que R1 hasta R5 y X están definidos como en la reivindicación 1, sus isómeros y sus sales, en particular sus sales fisiológicamente compatibles, que presentan valiosas propiedades farmacológicas, en particular un efecto inhibidor sobre diferentes tirosina-cinasas de receptores y complejos de ciclinas y CDK, así como sobre la proliferación de células endoteliales diferentes células tumorales, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación.The present invention relates to indolinones substituted in position 6 of the general formula (I) in which R1 to R5 and X are defined as in claim 1, their isomers and their salts, in particular their physiologically compatible salts, which have valuable Pharmacological properties, in particular an inhibitory effect on different receptor tyrosine kinases and cyclin and CDK complexes, as well as on the proliferation of different tumor cell endothelial cells, medications containing these compounds, their use and procedures for their preparation.
UY27241A2002-04-042002-04-04
INDOLINONES REPLACED IN POSITIONS 6, ITS PREPARATION AND USE AS MEDICATIONS
UY27241A1
(en)
Compounds derived from pyrrole (2.3-d) pyrimidine. purin-6-yl or pyrazol (3,4-d) pyrimldine, p70 s6 kinase inhibitors; pharmaceutical composition; and use for the preparation of drugs useful in the treatment of colon adenocarcinomas and inhibition of angiogenesis.
2-ANILINOPIRIMIDINAS REPLACED AS INHIBITORS OF THE KINASE OF THE CELL CYCLE OR THE RECEIVER OF THE THYROSINE KINASE, ITS PREPARATION AND ITS USE AS MEDICATIONS